Immunologic Features in De Novo and Recurrent Glioblastoma Are Associated with Survival Outcomes
- 4 May 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (7), 800-810
- https://doi.org/10.1158/2326-6066.cir-21-1050
Abstract
Glioblastoma (GBM) is an immunologically "cold" tumor characterized by poor responsiveness to immunotherapy. Standard-of-care for GBM is surgical resection followed by chemoradiotherapy and maintenance chemotherapy. However, tumor recurrence is the norm, and recurring tumors are found frequently to have acquired molecular changes (e.g. mutations) that may influence their immunobiology. Here, we compared the immune contexture of de novo and recurrent GBM (rGBM) using high-dimensional cytometry and multiplex immunohistochemistry. Although myeloid and T cells were similarly abundant in de novo and rGBM, their spatial organization within tumors differed and was linked to outcomes. In rGBM, T cells were enriched and activated in perivascular regions and clustered with activated macrophages and fewer regulatory T cells. Moreover, higher expression of phosphorylated STAT1 by T cells in these regions at recurrence was associated with a favorable prognosis. Together, our data identify differences in the immunobiology of de novo and rGBM and identify perivascular T cells as potential therapeutic targets.Keywords
Other Versions
Funding Information
- The GBM Translational Center of Excellence (R01-CA197916)
- NIH (CA016520, CA210944, AI149680, AI155577, AI108545, AI082630)
This publication has 48 references indexed in Scilit:
- Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143Neuro-Oncology, 2017
- Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growthNature Communications, 2017
- Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell–Engaging Antibody and CD8 T CellsCancer Research, 2015
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent GliomaScience, 2014
- Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic levelJournal of Neuroimmunology, 2013
- A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumoursNature, 2011
- HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental TumorsClinical Cancer Research, 2010
- Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 PathwayMolecular Cancer Therapeutics, 2010
- Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockadeProceedings of the National Academy of Sciences of the United States of America, 2008
- A Perivascular Niche for Brain Tumor Stem CellsCancer Cell, 2007